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A patient with congenital factor VII deficiency underwent surgery for an inflammatory 
abdominal aortic aneurysm. No references in the literature have been found on the 
management ofthis coagulation defect in patients who require vascular surgery. We present 
one such case, with special reference to the perioperative management of  factor VII 
replacement therapy. (J Vasc Surg 1996;24:288-90.) 
Hemorrhagic omplications, particularly in pa- 
tients who have a coagulation defect, can result from 
aggressive surgical procedures. A patient with con- 
genital factor VI I  deficiency and an inflammatory 
abdominal aortic aneurysm, who was managed with 
factor VI I  concentrate during surgery, is described. 
References about hemostatic management in these 
patients have not been found in the literamre. To our 
knowledge,  this is the first case reported. 
CASE REPORT 
A 73-year-old man was referred for surgery of an asymp- 
tomatic abdominal aortic aneurysm. His medical history 
included mild essential hypertension and chronic obstruc- 
tive pulmonary disease. Ten naonths earlier he had a right 
hemispheric transient ischemic attack. He had no history of 
pathologic bleeding. On admission the physical examina- 
tion was normal except for a pulsatile abdominal mass. 
Coagulation studies howed a prothrombin activity of 
38% (34 seconds); activated partial thromboplasfin time, 
29 seconds (control, 30 seconds); fibrinogen, 301 mg%; 
and platelet count, 285,000/mm ~. Therefore, the follow- 
ing hepatic coagulation factors were selectively &ter- 
mined: factor VII activity, 13% (0.13 U/tal); factor II, 
91%; factor V, 100%; factor X, 100%. The results of the 
remainder of laboratory studies »vere normal. A computed 
tomographic (CT) scan demonstrated an inflammatory 
aortobiiliac aneurysm ö cm in diameter in the inffarenal 
abdominal aorta, 4.5 cm in the right common iliac artery, 
and 3 cm in the left common iliac artery. Angiography 
confirmed the CT findings and the absence of visceral, 
renal, or tun-oft artery disease. Duplex scanning of the 
carotid bifurcation revealed stenosis of less than 50%. An 
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angiographic scan of the supraaortic trunks then was 
performed and demonstrated mild stenosis ofboth internal 
carotid arteries. The results of a brain CT scan were 
normal. An echocardiographic scan and our remaining 
routine preoperative studies failed to show pathologic 
findings. 
After the induction of anesthesia, 1000 U factor VII 
concentrate (Factor VII Concentrate TIM 4 Immuno, 
Immuno AG, Vienna, Austria) was administered by inta'a- 
venous infusion over a period of 30 minutes. The aneurysm 
then was resected by the transperitoneal pproach, and a 
16 x 8 mm aortobifemoral collagen precoagulated Dacron 
graft (Hemashield, Meadox Medicals Inc., Oaldand, N.J.) 
was inserted. A Jackson-Pratt suction drainage system was 
left in the retroperitoneal space and was exteriorized 
through a counterincision i the leit groin to monitor 
retroperitoneal b eeding during the first 48 hours after 
surgery. 
Estimated blood loss was 1500 rel. Total fluid infusion 
during surgery was 8000 ml; 800 ml of bank blood and 600 
ml from an autotransfuser device were transfused. Pro- 
thrombin activity increased to 70% (18 seconds) during 
aortic clamping, and to 90% (14 seconds) at the end of the 
surgery. Hemoglobin levels were maintained over 10.5 
mg/dl  during surgery. 
The following laboratory parameters were monitored 
every 6 hours during the first 24 hours after surgery and 
once daily thereafter: prothrombin activity, activated partial 
thromboplastin time, factor VII activity, and hemoglobin 
level (Table I). No hemodynamic changes were detected. 
No bleeding problems »vere noted in relation to incisions or 
intravenous sites. Retroperitoneal drainage was less than 
100 ml in 48 hours. Factor VII activity levels were always 
over 10%, therefore replacement therapy was not required 
in the days after surgery. The subsequent course was 
uneventful, and the patient was discharged on the seventh 
day after surgery. No complications occurred during a 
16-month follow-up period. 
DISCUSSION 
Factor VI I  was first described by Koller et al. ~ in 
1951 as the accelerator o f thrombin  formation in the 
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Table I. Hemostatic ontrol after surgery 
Hours after surgery PA (%) PT (in sec) API"T (in sec) Factor VII (%) Hemoglobin ~q/dl) 
0 90 I4 46 48 10.5 
6 60 21 35 18 10.3 
12 52 25 43 17 10.3 
18 40 32 41 15 10.1 
24 32 40 28 13 10.1 
P.A, Prothrombin activity; PT, prothrombin time in seconds; APTF, activated partial thromboplastin me. 
presence oftissue thromboplastin a d calcium. Factor 
VII, a vitamin K-dependent factor produced by the 
liver, circulates in the plasma t a concentration f 0.5 
gg/rel. The first reported case offactor VII deficiency 
was described by Alexander et al? in the same year, 
under the name of serum prothrombin conversion 
accelerator (SPCA) deficiency. 
I:actor VII deficiency is inherited as an autosomal 
recessive trait. It affects men and women equally, and 
occurs at an incidence of 1 in 500,000. The gene for 
factor VII is found on chromosome 13, adjacent to 
the gene for factor X. 3,4 
Factor VII, in conjunction with its cofactors 
(tissue factor and calcium), initiates coagulation by 
activation ofa small amount offactor X as the first step 
in the extrinsic pathway of the coagulation cascade. 
Factor VII also is a major activator of factor IX. The 
pathogenesis offactor VII deficiency iscansed in some 
cases by the production of abnormal factor VII or to 
the lack of production of factor VII. It is well known 
that factor VII deficiency is the only clotting factor 
deficiency that causes an isolated, prolonged pro- 
thrombin time in the presence of a normal partial 
thromboplastin time. In the case reported hefe, 
partial thromboplastin time was normal and pro- 
thrombin activity was 38%. 
Factor VII deficiency is usually first observed as 
easy bruising, soft tissue hemorrhage, pistaxis, and, 
in women, menorrhagia and metrorrhagia. Hemar- 
throses occurs in severely affected patients and often 
may be as severe as that seen in patients who have 
hemophilia A or B. Intracranial hemorrhage, spe- 
cially in neonates, has been reported with an incidence 
much higher (16%) than that found in most other 
deficiency stares except factor I and factor XII defi- 
ciency. The objective of the treatment in these cases is 
to achieve an increase to 15% to 25% of normal 
activity. Fresh plasma, factor IX concentrates (con- 
taining aetivated factor VII), 5 or factor VII concen- 
trates can be used for this purpose. The half-life of 
faetor VII is short (4 to 6 hours) and it has a rapid 
extravascular diffusion; therefore, it is very difficult o 
maintain ormal factor VII levels with plasma replace- 
ment herapy alone. Ragni et al. 6 reported three cases 
and reviewed the literature, concluding that he use of 
concentrates offactor VII is the best choice for central 
nervous ystem hemorrhage. 
Most reports have recommended replacement 
therapy for patients with congenital factor VII defi- 
ciency who must undergo surgery. Yorke and Mahr, 4 
however, after a review of 13 cases, suggeSted that 
routine preoperative clotting factor eplacement may 
not be required in congenital factor VII deficiency. 
More than 50% of these 13 cases were related with 
a minor nonaggressive operation. 
Briët and Onvlee 7used continuous plasma infu- 
sion for factor VII replacement in a patient who 
underwent total hip replacement. The aim of the 
authors was to maintain factor VII activity levels in 
excess of 10% for the first 4 days (including the day of 
surgery), in excess of 5% until day 10, and in excess of 
2% until day 20. Plasmapheresis was required five 
times to prevent overload. Curiously, this patient was 
reported on again 5 years later because of a revised 
total hip procedure. 8 On this occasion, however, the 
authors used factor VII concentrate with satisfactory 
results, which illustrates the change produced in the 
management of this kind of patients. 
Greene t al? performed surgery for scoliosis in a 
14-year-old boy with severe factor VII deficiency by 
using factor VII concentrate (50 U /kg  of body 
weight) before surgery and every 8 hours after surgery 
for the first 24 hours and by using fresh plasma for 5 
days. The authors believed that the replacement 
therapy must be individualized according to the type 
of surgery. They suggested that for surgery that 
involves aminimum ofdissection, a single transfusion 
of plasma may be all that is required. 
The patient whose case is presented here had a 
congenital factor VII deficiency, 13% of factor VII 
activity levels, and no history of bleeding disorders. 
Although it was not a severe faetor VII deficiency, the 
patient had to undergo an aggressive surgical proce- 
dure. For this reason, we decided to use replacement 
therapy during surgery. We ehose an infusion offactor 
VII concentrate instead of fresh plasma to avoid fluid 
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overload and to reduce the risk ofviral transmission. 
Factor VI I  Conccntrate T IM 4 Immuno is prcparcd 
from pooled human plasma. Plasma units are ob- 
tained exclusively from licensed plasmapheresis cen- 
ters in Europe and the United States. For the manu- 
facturc of factor VI I  concentrate, only plasma units 
that were nonreactive in tests for HBs antigen as well 
as for HIV- 1, HIV-2, and HCV antibodies were used. 
To further educe the potential risk ofviral transmis- 
sion the product is steam-treated under product- 
specific onditions (at 60 ° C for 10 hours, at 80 ° C for 
1 hour) during its production. 
Clinical and laboratory coagulation control are 
crucial during the first 2 days after surgery. Routine 
replacement therapy after snrgery is not always nec- 
essary. In our patient, factor VI I  activity levels, pro- 
thrombin time, and the clinical status after surgery did 
not warrant replacement therapy. 
Several cases ofthromboses in relation to the use 
ofprothrombin-complex concentrates have been re- 
ported. 9 To avoid thrombotic complications in a 
vascular patient, we used a perioperative r placcment 
therapy oflow-dose factor VI I  concentrate (15 U per 
kg ofbody weight). This dosage is sufficient to achieve 
normal hemostasis during major surgery. 
In our setting, patients with aortic aneurysms 
normally receive aprotinin (Trasylol, Bayer, Ger- 
many) during the operation. We did not use aprotinin 
in our patient, however, because the possible interac- 
tions between faetor VI I  concentrate and aprotinin 
are not known. 
There are no refcrences in the literature about 
hemostatic control during vascular surgery in patients 
with congenital factor VI I  deficiency. We believe that 
the use ofreplacement therapy is indicated in patients 
with this coagulation defect who undergo an aggres- 
sive surgical procedure with extensive retroperitoneal 
dissection. Factor VII  concentrate achieved bettet 
hemodynamic and hemostatic ontrol, as shown by 
our case. This approach might be useful in patients 
with other vascnlar conditions. 
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